Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) CFO Terrance Coyne sold 69,582 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $39.35, for a total transaction of $2,738,051.70. Following the sale, the chief financial officer owned 36,010 shares in the company, valued at $1,416,993.50. The trade was a 65.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Royalty Pharma Price Performance

RPRX traded up $0.29 during trading on Friday, hitting $40.40. 3,533,985 shares of the company traded hands, compared to its average volume of 3,959,286. The company has a market cap of $23.32 billion, a PE ratio of 30.61, a P/E/G ratio of 1.52 and a beta of 0.43. Royalty Pharma PLC has a 1 year low of $29.66 and a 1 year high of $41.70. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. The stock’s 50-day simple moving average is $39.32 and its two-hundred day simple moving average is $37.52.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. The company had revenue of $609.29 million during the quarter, compared to analyst estimates of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. As a group, sell-side analysts anticipate that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be given a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a dividend yield of 2.3%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date is Friday, February 20th. Royalty Pharma’s dividend payout ratio (DPR) is presently 66.67%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on RPRX. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. Weiss Ratings lowered shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. TD Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. The Goldman Sachs Group started coverage on shares of Royalty Pharma in a report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective for the company. Finally, Leerink Partners set a $45.00 price objective on shares of Royalty Pharma in a research report on Thursday, December 11th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $45.60.

Institutional Investors Weigh In On Royalty Pharma

Large investors have recently modified their holdings of the business. Royal Bank of Canada increased its position in shares of Royalty Pharma by 367.7% in the first quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock valued at $6,342,000 after buying an additional 160,191 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Royalty Pharma by 20.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock worth $2,490,000 after acquiring an additional 13,489 shares in the last quarter. Focus Partners Wealth purchased a new stake in Royalty Pharma in the 1st quarter worth $264,000. Intech Investment Management LLC raised its position in Royalty Pharma by 41.0% during the first quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock worth $1,494,000 after acquiring an additional 13,951 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Royalty Pharma by 23.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 20,201 shares of the biopharmaceutical company’s stock valued at $735,000 after purchasing an additional 3,841 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.